NORATEST: An e-Health solution for a better Alzheimer's diagnosis and management

Informazioni relative al progetto

NORATEST

ID dell’accordo di sovvenzione: 887507

DOI

10.3030/887507

Progetto chiuso

Data della firma CE 19 Novembre 2019

Data di avvio 1 Dicembre 2019

Data di completamento 31 Marzo 2020

Finanziato da

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

ALZOHIS
France

Periodic Reporting for period 1 - NORATEST (NORATEST: An e-Health solution for a better Alzheimer's diagnosis and management)

Periodo di rendicontazione: 2019-12-01 al 2020-03-31

Sintesi del contesto e degli obiettivi generali del progetto

Alzheimer’s disease (AD) is one of the most common diseases in the ageing population, ranking as the fifth leading cause of death. It affects more than 50 Million people worldwide and generates annual expenses near to €1 Trillion in total caring costs. Current tools to diagnose AD are expensive, inaccurate, invasive and in most cases, they are able to detect the disease only at advanced stages, which reduce the chances of treatment. With NoraTest, ALZOHIS will provide a timely and cost-effective method for AD diagnosis, which will allow the detection of symptoms earlier than the current methods, thus reducing the impact and cost of AD on society. NoraTest is based in a simple blood test analysis coupled to an analytical algorithm which provides an accurate score regarding the possibility of having AD.
The goal of this feasibility study was to assess the viability of NoraTest from a technical, regulatory, commercial and financial perspective. Our study shows that NoraTest is a solid project that will generate important benefits for our company. By 2025, ALZOHIS expects cumulative gross profits of over €28 Million, with a payback period of less than 4 years.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

During Phase 1 of NoraTest project we analyzed the technical features of our product and determined which improvements are needed to obtain a highly accurate and predictive algorithm for the diagnostic of Alzheimer’s disease. Moreover, we designed a development plan complying with all regulatory policies for the commercialization of NoraTest in the EU and US. We carefully analyzed the market with its trends and barriers. We developed a detailed exploitation and dissemination plan and a strong IPR strategy to protect our invention. Finally, we performed a financial analysis demonstrating that NoraTest project is profitable with an expected 5-years ROI of 1.73.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

With an additional investment of €2.9 Million, we will be able to complete NoraTest project for international commercialization. We expect to launch NoraTest in France by Q4 2020 and then expand to the rest of Europe and the US. We expect a total revenue of €18.2 Million by 2025, while generating 10 new job positions. Besides, by introducing NoraTest onto the market, we will provide an accurate tool for early detection of Alzheimer’s disease which will positively impact patients, families, the healthcare system and even neurobiology research.

noratest-img.png